Preclinical laboratory evaluation of a bivalent Staphylococcus aureus saccharide-exotoxin A protein conjugate vaccine

Human Vaccines

Volumn 2, Issue 3, 2006, Pages 89-98

  Ho, Mei M ^a   Bolgiano, Barbara ^a   Martino, Angela ^a   Kairo, Satnam K ^a   Corbel, Michael J ^a  

^a NATIONAL INSTITUTE FOR BIOLOGICAL STANDARDS AND CONTROL   (United Kingdom)

Author keywords

Circular dichroism; Conjugate vaccine; Exotoxin; Multi angle laser light scattering; Noscomial; Polysaccharide; S. aureus

Indexed keywords

BACTERIAL POLYSACCHARIDE; CARRIER PROTEIN; IMMUNOGLOBULIN G; POLYSACCHARIDE TYPE 5; POLYSACCHARIDE TYPE 8; RECOMBINANT PROTEIN; RECOMBINANT PSEUDOMONAS AERUGINOSA EXOTOXIN A; RECOMBINANT VACCINE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; CYTOTOXICITY; DOSE RESPONSE; DRUG CONFORMATION; DRUG CONJUGATION; DRUG SAFETY; DRUG STABILITY; DRUG STRUCTURE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FLUORESCENCE SPECTROSCOPY; IMMUNE RESPONSE; IMMUNOGENICITY; IMMUNOGLOBULIN BLOOD LEVEL; LABORATORY TEST; MOUSE; NONHUMAN; PHYSICAL CHEMISTRY; STAPHYLOCOCCUS AUREUS; THERMOSTABILITY; TOXICITY TESTING;

EID: 33748035743     PISSN: 15548600     EISSN: 15548619     Source Type: Journal    
DOI: 10.4161/hv.2755     Document Type: Article

References (31)

1. Duckworth G, Cookson B, Pearson A, Crowcroft N. Surveillance for S aureus bacteraemias is compulsory. BMJ 2002; 324:240-41.
2. Tiemersma EW, Bronzwaer SL, Lyytikainen O, Degener JE, Schrijnemakers P, Bruinsma N, Monen J, Witte W, Grundman H; European Antimicrobial Resistance Surveillance System Participants. Methicillin-resistant Staphylococcus aureus in Europe, 1999-2002. Emerg Infect Dis 2004; 10:1627-34.
3. Shinefield H, Black S, Fattom A, Horwith G, Rasgon S, Ordonez J, Yeoh H, Law D, Robbins JB, Schneerson R, Muenz L, Fuller S, Johnson J, Fireman B, Alcorn H, Naso R. Use of a Staphylococcus aureus conjugate vaccine in patients receiving hemodialysis. N Engl J Med 2002; 346:491-96.
4. Sompolinsky D, Samra Z, Karakawa WW, Vann WF, Schneerson R, Malik Z. Encapsulation and capsular types in isolates of Staphylococcus aureus from different sources and relationship to phage types. J Clin Microbiol 1985; 22:828-34.
5. Na'was T, Hawwari A, Hendrix E, Hebden J, Edelman R, Martin M, Campbell W, Naso R, Schwalbe R, Fattom AI. Phenotypic and genotypic characterization of nosocomial Staphylococcus aureus isolates from trauma patients. J Clin Microbiol 1998; 36:414-20.
6. Fattom A, Schneerson R, Szu SC, Vann WF, Shiloach J, Karakawa WW, Robbins JB. Synthesis and immunologic properties in mice of vaccines composed of Staphylococcus aureus type 5 and type 8 capsular polysaccharides conjugated to Pseudomonas aeruginosa exotoxin A. Infect Immun 1990; 58:2367-74.
7. Fattom A, Shiloach J, Bryla D, Fitzgerald D, Pastan I, Karakawa WW, Robbins JB, Schneerson R. Comparative immunogenicity of conjugates composed of the Staphylococcus aureus type 8 capsular polysaccharide bound to carrier proteins by adipic acid dihydrazide or N-succinimidyl-3- (2-pyridyldithio) propionate. Infect Immun 1992; 60:584-89.
8. Fattom AI, Horwith G, Fuller S, Propst M, Naso R. Development of StaphVAX, a polysaccharide conjugate vaccine against S. aureus infection: From the lab bench to phase III clinical trials. Vaccine 2004; 22:880-87.
9. Allured VS, Collier RJ, Carroll SF, McKay DB. Structure of exotoxin A of Pseudomonas aeruginosa at 3.0-Angstrom resolution. Proc Natl Acad Sci USA 1986; 83:1320-24.
10. Wedekind JE, Trame CB, Dorywalska M, Koehl P, Raschke TM, McKee M, FitzGerald D, Collier RJ, McKay DB. Refined crystallographic structure of Pseudomonas aeruginosa exotoxin A and its implications for the molecular mechanism of toxicicy. J Mol Biol 2001; 314:823-37.
11. Killeen KP, Collier RJ. Conformational integrity of a recombinant toxoid of Pseudomonas aeruginosa exotoxin A containing a deletion of glutamic acid-553. Biochim Biophys Acta 1992; 1138:162-66.
12. Jones C. Revised structures for the capsular polysaccharides from Staphylococcus aureus Types 5 and 8, components of novel glycoconjugate vaccines. Carbohydr Res 2005; 340:1097-106.
13. Moreau M, Richards JC, Fournier JM, Byrd RA, Karakawa WW, Vann WF. Structure of the type 5 capsular polysaccharide of Staphylococcus aureus. Carbohydr Res 1990; 201:285-97.
14. Vann WF, Moreau M, Sutton A, Byrd RA, Karakawa WW. Structure and immunochemistry of Staphylococcal aureus capsular polysaccharides. In: Horowitz MA, ed. Bacterial-Host cell Interaction. Liss, New York: 1988:187-98.
15. Fowler S, Xing DK, Bolgiano B, Yuen CT, Corbel MJ. Modifications of the catalytic and binding subunits of pertussis toxin by formaldehyde: Effects on toxicity and immunogenicity. Vaccine 2003; 21:2329-37.
16. European Pharmacopoeia. Bacterial endotoxins test. Strasbourg, Cedex, France: Directorate for the Quality of Medicines of the Council of Europe (EDQM), 2005:161-68.
17. Gaines Das RE, Brugger P, Patel M, Mistry Y, Poole S. Monocyte activation test for pro-inflammatory and pyrogenic contaminants of parenteral drugs: Test design and data analysis. J Immunol Methods 2004; 288:165-77.
18. Poole S, Mistry Y, Ball C, Gaines Das RE, Opie LP, Tucker G, Patel M. A rapid 'one-plate' in vitro test for pyrogens. J Immunol Methods 2003; 274:209-20.
19. Bloemendal M, Johnson Jr WC. Structural information on proteins from circular dichroism spectroscopy possibilities and limitations. Pharm Biotechnol 1995; 7:65-100.
20. Manavalan P, Johnson Jr WC. Variable selection method improves the prediction of protein secondary structure from circular dichroism spectra. Anal Biochem 1987; 167:76-85.
21. Collins CM, Collier RJ. Circular dichroism of diphtheria toxin, Pseudomonas aeruginosa exotoxin A, and various derivatives. Biochim Biophys Acta 1985; 828:138-43.
22. Kaluarachchi K, Bush CA. Determination of the absolute configuration of the sugar residues of complex polysaccharides by circular dichroism spectroscopy. Anal Biochem 1989; 179:209-15.
23. Jiang JX, London E. Involvement of denaturation-like changes in Pseudomonas exotoxin a hydrophobicity and membrane penetration determined by characterization of pH and thermal transitions. Roles of two distinct conformationally altered states. J Biol Chem 1990; 265:8636-41.
24. Jumel K, Ho MM, Bolgiano B. Evaluation of meningococcal C oligosaccharide conjugate vaccines by size-exclusion chromatography/multi-angle laser light scattering. Biotechnol Appl Biochem 2002; 36:219-26.
25. Ho MM, Mawas F, Bolgiano B, Lemercinier X, Crane DT, Huskisson R, Corbel MJ. Physico-chemical and immunological examination of the thermal stability of tetanus toxoid conjugate vaccines. Vaccine 2002; 20:3509-22.
26. Ho MM, Bolgiano B, Corbel MJ. Assessment of the stability and immunogenicity of meningococcal oligosaccharide C-CRM197 conjugate vaccines. Vaccine 2000; 19:716-25.
27. Bolgiano B, Mawas F, Yost SE, Crane DT, Lemercinier X, Corbel MJ. Effect of physicochemical modification on the immunogenicity of Haemophilus influenzae type b oligosaccharide-CRM(197) conjugate vaccines. Vaccine 2001; 19:3189-200.
28. Talaga P, Vialle S, Moreau M. Development of a high-performance anion-exchange chromatography with pulsed-amperometric detection based quantification assay for pneumococcal polysaccharides and conjugates. Vaccine 2002; 20:2474-84.
29. Karakawa WW, Sutton A, Schneerson R, Karpas A, Vann WF. Capsular antibodies induce type-specific phagocytosis of capsulated Staphylococcus aureus by human polymorphonuclear leukocytes. Infect Immun 1988; 56:1090-95.
30. Fattom A, Schneerson R, Watson DC, Karakawa WW, Fitzgerald D, Pastan I, Li X, Shiloach J, Bryla DA, Robbins JB. Laboratory and clinical evaluation of conjugate vaccines composed of Staphylococcus aureus type 5 and type 8 capsular polysaccharides bound to Pseudomonas aeruginosa recombinant exoprotein A. Infect Immun 1993; 61:1023-32.
31. Fattom AI, Sarwar J, Ortiz A, Naso R. A Staphylococcus aureus capsular polysaccharide (CP) vaccine and CP-specific antibodies protect mice against bacterial challenge. Infect Immun 1996; 64:1659-65.